Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
Status PubMed-not-MEDLINE Language English Country United States Media print
Document type Published Erratum
PubMed
37923838
PubMed Central
PMC10878963
DOI
10.1038/s41591-023-02661-5
PII: 10.1038/s41591-023-02661-5
Knihovny.cz E-resources
- Publication type
- Published Erratum MeSH
Bristol Myers Squibb Princeton NJ USA
Cleveland Clinic Cleveland OH USA
Elbe Klinikum Buxtehude Buxtehude Germany
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Hôpital de la Timone Marseille France
Hôpital Saint André Bordeaux France
Institute of Oncology Poznan University of Medical Sciences Poznan Poland
Istituto Nazionale Tumori IRCCS 'Fondazione G Pascale' Naples Italy
Istituto Oncologico Veneto IOV IRCCS Padova Italy
Maria Skłodowska Curie National Research Institute of Oncology Warsaw Poland
Medizinische Universität Wien Vienna Austria
Nantes University Hospital Nantes France
NYU Langone Medical Center New York NY USA
University Medical Center Mainz Mainz Germany
University of Western Australia and Sir Charles Gairdner Hospital Perth WA Australia
References provided by Crossref.org
